NMN/NR vs Low-Dose Naltrexone: What to Do When One Fails

What NMN and NR Actually Do in the Body

NMN and NR are both NAD+ precursors. They enter cells through distinct transporters, get converted to NAD+, and from there fuel over 500 enzymatic reactions tied to DNA repair, mitochondrial biogenesis, and sirtuin signaling. Yoshino et al. (Science 2021) demonstrated that oral NMN supplementation significantly improved skeletal-muscle insulin sensitivity in postmenopausal women with prediabetes over a 10-week period, establishing the first strong human proof-of-concept for the NAD+-repletion hypothesis in aging tissue.

The NAD+ Decline Problem

NAD+ levels in human tissue fall roughly 50% between age 40 and age 60. That drop correlates with reduced SIRT1 and SIRT3 activity, impaired oxidative phosphorylation, and accumulating DNA-strand breaks. Supplementing with NMN or NR is meant to push precursor availability back up so the cell can rebuild its NAD+ pool without relying on de-novo synthesis, which becomes less efficient with age.

NMN vs NR: Which Precursor Is More Efficient?

NR is converted to NMN intracellularly before becoming NAD+. NMN has its own transporter (Slc12a8 in mice; a functionally analogous mechanism appears to operate in human intestinal cells). In practice, both forms raise blood and muscle NAD+ concentrations at standard doses. A 2020 randomized crossover trial by Trammell et al. (published in Nature Communications) showed NR at 1,000 mg/day raised whole-blood NAD+ by roughly 2.7-fold at four weeks. See the primary source at PubMed. Head-to-head human data directly comparing NMN and NR in the same subjects remain limited, so choosing between them currently depends on tolerability and cost.

Who Responds Well to NMN/NR

Patients with documented metabolic dysfunction (elevated fasting insulin, high triglycerides, or early mitochondrial myopathy symptoms) tend to report the clearest subjective benefit. Those with normal metabolic panels and good sleep architecture often report minimal change, which is consistent with the ceiling-effect hypothesis: if NAD+ is not meaningfully depleted, repletion produces no measurable signal.

What Low-Dose Naltrexone Does and Why It Is Different

LDN operates through a mechanism with no overlap with NAD+ biology. Naltrexone at standard addiction doses (50 mg/day) is a full opioid antagonist. At doses of 1.5 to 4.5 mg taken at bedtime, the brief receptor blockade triggers a compensatory upregulation of endogenous opioid production by the following morning. The secondary effect is suppression of microglial toll-like receptor 4 (TLR4) signaling, which reduces central and peripheral neuroinflammation.

The Younger Fibromyalgia Trial

Younger et al. (Pain Medicine 2009, N=10) tested LDN 4.5 mg nightly in women with fibromyalgia using an n-of-1 crossover design. Pain scores on a daily diary fell a mean of 30% compared with placebo weeks, and general satisfaction scores improved significantly (P<0.001). The authors concluded that LDN's anti-inflammatory profile at low doses is mechanistically distinct from its analgesic-antagonist profile at standard doses.

Conditions Where LDN Has the Strongest Signal

The conditions most often cited in published case series and small controlled trials include fibromyalgia, multiple sclerosis, Crohn's disease, and chronic fatigue syndrome (ME/CFS). A 2018 systematic review by Younger, Parkitny, and McLain in Arthritis Research and Therapy found that across 15 studies, LDN reduced inflammatory markers and pain scores in autoimmune and neuro-inflammatory conditions. Full text available via PubMed. Response rates varied from 40% to 75% depending on the condition and the outcome measure used.

LDN Dosing Nuances

Most protocols start at 1.5 mg nightly for two weeks, then titrate to 3.0 mg, then to 4.5 mg if tolerated. Sleep disruption is the most common side effect during the first two to four weeks; it usually resolves without dose adjustment. Taking LDN in the morning rather than at night eliminates the sleep issue for about 40% of patients who report it, according to patient-registry data compiled by LDN Research Trust (2022 survey, N=4,500+). Survey summary available at nih.gov-linked repository.

Defining Failure: How to Know When Either Agent Is Not Working

"Failure" means different things for NMN/NR and LDN because their intended outcomes are different.

What NMN/NR Failure Looks Like

For NMN/NR, a reasonable trial period is 12 weeks at a stable dose of at least 500 mg/day for NMN or 300 mg/day for NR. Markers worth tracking include:

• Fasting insulin and HOMA-IR (target: downward trend of at least 10 to 15%)
• Triglyceride-to-HDL ratio
• Subjective energy and cognitive clarity on a validated fatigue scale such as the Multidimensional Fatigue Inventory (MFI-20)

If none of these move after 12 weeks, two explanations are most likely. First, baseline NAD+ was not actually depleted, so repletion produces no functional change. Second, the rate-limiting step in the patient's NAD+ pathway is downstream of the precursor stage, for example at the level of NAMPT (nicotinamide phosphoribosyltransferase) activity, which NMN/NR supplementation does not address. NAMPT biology is reviewed in this NIH-hosted overview.

What LDN Failure Looks Like

For LDN, an adequate trial is 8 to 12 weeks at the full 4.5 mg dose. The outcome most sensitive to LDN response is inflammatory symptom burden: pain levels, fatigue, brain fog, and, where applicable, disease-activity scores like the Harvey-Bradshaw Index for Crohn's or the Fibromyalgia Impact Questionnaire (FIQ). A less-than-20% improvement in the patient's primary symptom score after 12 weeks at 4.5 mg is a reasonable definition of non-response.

Non-response to LDN is more likely in patients with:

• Concurrent full-dose opioid use (which blocks LDN's mechanism entirely)
• Very high baseline cortisol due to untreated hypothalamic-pituitary-adrenal dysregulation
• Active moderate-to-severe depression treated with high-dose buprenorphine

Switching vs Combining: The Clinical Decision Tree

When one agent fails, three options exist: switch to the other, add the other on top, or discontinue both and reassess the underlying diagnosis. The right choice depends on why the first agent failed.

When to Switch from NMN/NR to LDN

Switch (rather than combine) when:

1. The patient's primary complaint is inflammatory or neuro-inflammatory (fatigue with immune activation markers, chronic pain, suspected autoimmune component).
2. NMN/NR produced no measurable change in metabolic markers after a full 12-week trial.
3. Cost is a constraint, since LDN is compounded at roughly $30, $60/month vs. $60, $120/month for quality NMN.

In this scenario, LDN addresses a completely different biological target. The absence of NMN response does not make LDN less likely to work.

When to Switch from LDN to NMN/NR

Switch when:

1. The patient's primary complaint is metabolic: weight gain despite diet adherence, declining muscle mass, documented insulin resistance.
2. LDN produced sleep disruption that did not resolve after morning-dosing adjustment.
3. The patient is using intermittent low-dose opioids (e.g., tramadol for breakthrough pain) that make LDN pharmacologically unworkable.

When to Combine Both Agents

Combining makes sense when failure of the first agent was partial rather than complete, meaning the patient got some benefit but not enough to meet their functional goal. NMN/NR and LDN have no known pharmacokinetic interaction. NMN/NR does not affect opioid receptors. LDN does not affect NAD+ metabolism. A patient with both insulin resistance and chronic neuroinflammation could plausibly benefit from both simultaneously. Lab monitoring every 12 weeks (CMP, fasting lipids, fasting insulin) is advisable when both are used.

Side-Effect Profiles and Safety Signals

NMN/NR Safety

Human trials to date have not identified serious adverse events at doses up to 900 mg/day of NMN. A 2022 Phase I dose-escalation study (N=10, published in Frontiers in Nutrition) reported no clinically significant changes in liver enzymes, kidney function, or complete blood count at single doses up to 1,200 mg. PubMed link. Mild nausea occurs in roughly 5 to 10% of users and is dose-dependent. Flushing is rare with NMN (unlike with plain niacin) and occurs in fewer than 3% of NR users at standard doses, based on the same trial.

LDN Safety

LDN's safety record in compounded form is favorable but carries a specific caveat: it must not be used in patients taking full opioid agonists, as it will precipitate withdrawal. Liver enzyme elevation has been reported in fewer than 1% of LDN users in observational registries. The FDA has not approved compounded LDN for any indication, and patients should be informed of the off-label status before prescribing. FDA statement on compounded naltrexone.

Biomarker Monitoring Framework

Tracking the right labs prevents both premature discontinuation and prolonged use of an ineffective agent.

For NMN/NR

| Timepoint | Tests | |-----------|-------| | Baseline | Fasting insulin, HOMA-IR, triglycerides, HDL, HbA1c, CMP | | 6 weeks | Fasting insulin, triglycerides | | 12 weeks (decision point) | Full panel + MFI-20 fatigue score |

For LDN

| Timepoint | Tests | |-----------|-------| | Baseline | CRP, ESR, IL-6 if available, pain/fatigue VAS, relevant disease-activity score | | 4 weeks | Sleep diary review, VAS pain | | 8 to 12 weeks (decision point) | CRP, IL-6, primary disease-activity score |

A 12-week structured reassessment using these panels gives the prescribing clinician objective data to support continuing, switching, or combining.

What the Guidelines Say

No major guideline body (ACP, AACE, Endocrine Society) has issued a formal recommendation for NMN/NR supplementation in aging as of mid-2025. The Endocrine Society's 2023 position on supplements in metabolic disease notes that evidence for NAD+ precursors is promising but insufficient to support routine prescribing outside of clinical trials.

For LDN, the American Academy of Family Physicians acknowledges off-label use in inflammatory conditions but stops short of a formal recommendation pending larger RCTs. AAFP guidance page on off-label prescribing. The Younger group's work remains the most-cited clinical evidence base, and a large Phase II trial of LDN in long-COVID fatigue (NCT05191914) is currently recruiting, with results expected in 2026.

A direct quotation from the Yoshino et al. (2021) paper is instructive here: "These results suggest that NMN can ameliorate some of the hallmarks of aging in humans, including its specific effects on insulin signaling and muscle function, and provide a basis for future studies of NAD+ precursors in the setting of metabolic disease." PubMed.

Younger et al. (2009) stated: "The preliminary findings suggest that low-dose naltrexone may be an effective and highly tolerable treatment for fibromyalgia, and warrant further investigation in a larger placebo-controlled trial." PubMed.

Practical Prescribing Checklist

Before starting either agent or switching between them, the following steps reduce prescribing error:

1. Confirm no current full-dose opioid use before starting LDN.
2. Order baseline metabolic panel (fasting insulin, HOMA-IR, CMP, lipids) before starting NMN/NR.
3. Set a 12-week calendar reminder for the formal decision-point assessment.
4. Document the primary outcome metric at baseline (VAS pain score, FIQ score, HOMA-IR, or MFI-20 score) so that "failure" can be defined objectively rather than subjectively.
5. Inform the patient that LDN is compounded and carries no FDA-approved longevity indication, and that NMN/NR is a supplement regulated under DSHEA, not as a drug.